Jennifer E Schuster1, Jenna O Miller2, Rangaraj Selvarangan3, Gina Weddle4, Marita T Thompson2, Ferdaus Hassan3, Shannon L Rogers5, M Steven Oberste5, W Allan Nix5, Mary Anne Jackson4. 1. Division of Infectious Diseases, Children's Mercy Hospital, Kansas City, MO, USA. Electronic address: jeschuster@cmh.edu. 2. Division of Critical Care, Children's Mercy Hospital, Kansas City, MO, USA. 3. Division of Pathology and Laboratory Medicine, Children's Mercy Hospital, Kansas City, MO, USA. 4. Division of Infectious Diseases, Children's Mercy Hospital, Kansas City, MO, USA. 5. Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA.
Abstract
BACKGROUND: Enterovirus 68 (EV-D68) causes acute respiratory tract illness in epidemic cycles, most recently in Fall 2014, but clinical characteristics of severe disease are not well reported. OBJECTIVES: Children with EV-D68 severe respiratory disease requiring pediatric intensive care unit (PICU) management were compared with children with severe respiratory disease from other enteroviruses/rhinoviruses. STUDY DESIGN: A retrospective review was performed of all children admitted to Children's Mercy Hospital PICU from August 1-September 15, 2014 with positive PCR testing for enterovirus/rhinovirus. Specimens were subsequently tested for the presence of EV-D68. We evaluated baseline characteristics, symptomatology, lab values, therapeutics, and outcomes of children with EV-D68 viral infection compared with enterovirus/rhinovirus-positive, EV-D68-negative children. RESULTS: A total of 86 children with positive enterovirus/rhinovirus testing associated with respiratory symptoms were admitted to the PICU. Children with EV-D68 were older than their EV-D68-negative counterparts (7.1 vs. 3.5 years, P=0.01). They were more likely to have a history of asthma or recurrent wheeze (68% vs. 42%, P=0.03) and to present with cough (90% vs. 63%, P=0.009). EV-D68 children were significantly more likely to receive albuterol (95% vs. 79%, P=0.04), magnesium (75% vs. 42%, P=0.004), and aminophylline (25% vs. 4%, P=0.03). Other adjunctive medications used in EV-D68 children included corticosteroids, epinephrine, and heliox; 44% of EV-D68-positive children required non-invasive ventilatory support. CONCLUSIONS: EV-D68 causes severe disease in the pediatric population, particularly in children with asthma and recurrent wheeze; children may require multiple adjunctive respiratory therapies.
BACKGROUND:Enterovirus 68 (EV-D68) causes acute respiratory tract illness in epidemic cycles, most recently in Fall 2014, but clinical characteristics of severe disease are not well reported. OBJECTIVES:Children with EV-D68 severe respiratory disease requiring pediatric intensive care unit (PICU) management were compared with children with severe respiratory disease from other enteroviruses/rhinoviruses. STUDY DESIGN: A retrospective review was performed of all children admitted to Children's Mercy Hospital PICU from August 1-September 15, 2014 with positive PCR testing for enterovirus/rhinovirus. Specimens were subsequently tested for the presence of EV-D68. We evaluated baseline characteristics, symptomatology, lab values, therapeutics, and outcomes of children with EV-D68viral infection compared with enterovirus/rhinovirus-positive, EV-D68-negative children. RESULTS: A total of 86 children with positive enterovirus/rhinovirus testing associated with respiratory symptoms were admitted to the PICU. Children with EV-D68 were older than their EV-D68-negative counterparts (7.1 vs. 3.5 years, P=0.01). They were more likely to have a history of asthma or recurrent wheeze (68% vs. 42%, P=0.03) and to present with cough (90% vs. 63%, P=0.009). EV-D68children were significantly more likely to receive albuterol (95% vs. 79%, P=0.04), magnesium (75% vs. 42%, P=0.004), and aminophylline (25% vs. 4%, P=0.03). Other adjunctive medications used in EV-D68children included corticosteroids, epinephrine, and heliox; 44% of EV-D68-positive children required non-invasive ventilatory support. CONCLUSIONS:EV-D68 causes severe disease in the pediatric population, particularly in children with asthma and recurrent wheeze; children may require multiple adjunctive respiratory therapies.
Authors: W Joseph Evans; Brett L Hurst; Christopher J Peterson; Arnaud J Van Wettere; Craig W Day; Donald F Smee; E Bart Tarbet Journal: Antiviral Res Date: 2018-12-03 Impact factor: 5.970
Authors: Yi Tan; Ferdaus Hassan; Jennifer E Schuster; Ari Simenauer; Rangaraj Selvarangan; Rebecca A Halpin; Xudong Lin; Nadia Fedorova; Timothy B Stockwell; Tommy Tsan-Yuk Lam; James D Chappell; Tina V Hartert; Edward C Holmes; Suman R Das Journal: J Virol Date: 2015-12-09 Impact factor: 5.103
Authors: Suchitra Rao; Kevin Messacar; Michelle R Torok; Anne-Marie Rick; Jeffrey Holzberg; Aaron Montano; Dayanand Bagdure; Donna J Curtis; M Steven Oberste; W Allan Nix; Gina de Masellis; Christine C Robinson; Samuel R Dominguez Journal: Pediatr Crit Care Med Date: 2016-11 Impact factor: 3.624
Authors: Holly M Biggs; Monica McNeal; W Allan Nix; Carolyn Kercsmar; Aaron T Curns; Beverly Connelly; Marilyn Rice; Shur-Wern Wang Chern; Mila M Prill; Nancy Back; M Steven Oberste; Susan I Gerber; Mary A Staat Journal: Clin Infect Dis Date: 2017-07-15 Impact factor: 9.079